Rock, if you're willing to wait and hold until Sep 2021 while the share price may very well dip below $2, I suppose that's one strategy to have. It's not mine.
Exactly right about your point of being left behind. Been there done that in a few pharmas and made out in others. This is a blockbuster. Will jump by leaps and bounds on any and all approvals. So this is why I buy any and all reactions to the downside. In the blink of an eye we will be back at ten bucks. The number of new investors and those now watching and waiting are thousands more than we had back just a few months ago. Every day we are getting closer to that day when the chatter stops because everyone is buying all they can. Any new investors should not be discouraged. Focus on the science. Leronlimab is here to stay and will be seen in hospitals around the globe. This company will have a significant impact raising the value of the global healthcare market. Few companies have the potential to do that beyond a blimp on the screen.
Market Data 
Markets 
AI
